Luspatercept通过MDS来源间充质基质细胞恢复SDF-1介导的造血支持
本研究探讨Luspatercept是否调节骨髓微环境中间充质基质细胞(MSCs)的功能。Luspatercept抑制健康及MDS MSCs中Smad2/3磷酸化,逆转SDF-1分泌异常;预处理MDS MSCs可恢复共培养HSPCs的克隆潜能、基质黏附及CXCR4和β3整合素表达,并增加斑马鱼胚胎中HSPCs归巢。来自接受Luspatercept治疗患者的MSCs增强维持正常而非MDS HSPCs集落形成的能力。
要点
- Luspatercept直接作用于MDS骨髓微环境中的MSCs。
- Luspatercept抑制MSCs中Smad2/3磷酸化并逆转SDF-1分泌异常。
- Luspatercept预处理MSCs选择性恢复正常而非MDS HSPCs的造血支持。
核心结论
- Luspatercept直接作用于骨髓微环境,选择性恢复MDS中无效造血。
研究设计与样本
- 体外研究:比较健康与MDS来源MSCs经Luspatercept处理后的功能变化,并分析接受Luspatercept治疗患者的MSCs。
主要发现
- Luspatercept抑制健康及MDS MSCs中Smad2/3磷酸化。
- Luspatercept逆转MDS MSCs中SDF-1分泌的疾病相关改变。
- Luspatercept预处理MDS MSCs恢复共培养HSPCs的克隆潜能,增加基质黏附及CXCR4和β3整合素表达。
- Luspatercept预处理MSCs增加斑马鱼胚胎中共培养HSPCs的归巢。
- 接受Luspatercept治疗患者的MSCs增强维持正常而非MDS HSPCs集落形成潜能的能力。
临床怎么用
- 提示Luspatercept可能通过改善骨髓微环境功能而发挥治疗作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The bone marrow microenvironment (BMME) plays a key role in the pathophysiology of myelodysplastic syndromes (MDS), clonal blood disorders affecting the differentiation, and maturation of hematopoietic stem and progenitor cells (HSPCs). In lower-risk MDS patients, ineffective late-stage erythropoiesis can be restored by luspatercept, an activin receptor type IIB ligand trap. Here, we investigated whether luspatercept can modulate the functional properties of mesenchymal stromal cells (MSCs) as key components of the BMME. Luspatercept treatment inhibited Smad2/3 phosphorylation in both healthy and MDS MSCs and reversed disease-associated alterations in SDF-1 secretion. Pre-treatment of MDS MSCs with luspatercept restored the subsequent clonogenic potential of co-cultured HSPCs and increased both their stromal-adherence and their expression of both CXCR4 and ß3 integrin. Luspatercept pre-treatment of MSCs also increased the subsequent homing of co-cultured HSPCs in zebrafish embryos. MSCs derived from patients who had received luspatercept treatment had an increased capacity to maintain the colony forming potential of normal but not MDS HSPCs. These data provide the first evidence that luspatercept impacts the BMME directly, leading to a selective restoration of the ineffective hematopoiesis that is a hallmark of MDS.
引用
- Wobus M, Mies A, Asokan N, et al. Luspatercept restores SDF-1-mediated hematopoietic support by MDS-derived mesenchymal stromal cells. Leukemia. 2021. PMID: 34002031. doi:10.1038/s41375-021-01275-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。